Introduction: We investigated the effects of hyperbaric oxygen (HBO)
therapy on post-stroke cognitive impairment (PSCI) and performed the
differential profiling of lncRNAs and mRNA.
Methods: The serum levels of different inflammatory factors were
detected in PSCI patients with or without HBO therapy. The cognitive
functions of patients in different groups were assessed before and after
treatment. Differential expression analysis was performed on lncRNAs
and mRNAs, followed by functional interaction prediction. The selected
candidates were verified by Real-time Quantitative PCR and luciferase
reporter assay.
Results: The results of MMSE and MoCA scores showed that patients in
both the control (conventional treatment) group and HBO therapy group
had significantly higher post-treatment cognitive scores, and in the 6th
month after treatment, patients in the HBO group had higher scores than
those in the control group. Blood inflammatory factors showed similar
results, with the HBO group having higher anti-inflammatory factors
IL-4 and IL-10 than the control group, and lower pro-inflammatory
factors IL-2, IL-6, TNF-α, IFN-α and IL-17A than the control group. We
further identified a competitive endogenous RNA regulator network of
LINC00205-hsa-miR-495-3p-TNFSF15 involved in the HBO treatment,
and their expression patterns were verified by qRT-PCR.
Conclusion: HBO treatment can improve the cognitive performance
of PSCI patients in comparison to conventional treatment scheme.
LINC00205/miR-495-3p/TNFSF15 axis may be responsible for the
treatment effect of HBO therapy.
Keywords: Bioinformatics analysis; ceRNA; hyperbaric oxygen; oxidative
stress; Post-stroke cognitive impairment; TNFSF15